Wall Street brokerages forecast that Axovant Sciences (NASDAQ:AXON) will post earnings of ($0.39) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Axovant Sciences’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.27). Axovant Sciences reported earnings of ($0.53) per share in the same quarter last year, which indicates a positive year over year growth rate of 26.4%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, June 12th.
According to Zacks, analysts expect that Axovant Sciences will report full-year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.32) to ($2.09). For the next year, analysts forecast that the firm will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Axovant Sciences.
A number of equities analysts have commented on AXON shares. ValuEngine cut Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Monday, April 2nd. Zacks Investment Research cut Axovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, February 14th. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Finally, Cowen reissued a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company’s stock. Axovant Sciences has a consensus rating of “Hold” and a consensus price target of $13.61.
Shares of Axovant Sciences stock traded down $0.08 during mid-day trading on Monday, reaching $1.22. 975,957 shares of the stock traded hands, compared to its average volume of 1,187,062. Axovant Sciences has a fifty-two week low of $1.02 and a fifty-two week high of $27.98. The stock has a market capitalization of $140.13 million, a P/E ratio of -0.67 and a beta of -0.37. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.58 and a quick ratio of 4.58.
In related news, Director George Bickerstaff purchased 25,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $37,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 72.40% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of AXON. BlackRock Inc. grew its position in Axovant Sciences by 99.8% in the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after acquiring an additional 1,454,454 shares during the period. Millennium Management LLC grew its position in Axovant Sciences by 175.6% in the first quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock worth $1,770,000 after acquiring an additional 847,946 shares during the period. Hudson Bay Capital Management LP purchased a new position in Axovant Sciences in the fourth quarter worth approximately $1,845,000. A.R.T. Advisors LLC grew its position in Axovant Sciences by 148.9% in the first quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 249,074 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Axovant Sciences by 2,519.0% in the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 176,227 shares during the period. Institutional investors own 14.83% of the company’s stock.
About Axovant Sciences
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.